NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, has announced the registration of its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo ebolavirus and other Ebola viruses in the Democratic Republic of Congo (DRC). The trial has been registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077, following local regulatory approval from ACOREP.
The company has confirmed that NV-387 has been delivered to the clinical trial site in Ituri province, with first patient dosing anticipated within one to two weeks, barring outbreak-related impediments. The adaptive trial will begin with a single-arm safety and dose run-in before progressing to a randomized, controlled, open-label efficacy evaluation.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. It is also being evaluated in a Phase II clinical trial for Mpox in the DRC, as indicated in the press release.
This development is significant because Ebola outbreaks remain a major public health threat in Central Africa. The current trial focuses on the Bundibugyo species, which has caused multiple outbreaks with high fatality rates. An effective oral treatment could greatly improve patient outcomes, especially in resource-limited settings where intravenous therapies are difficult to administer.
The trial's registration in the Pan African Clinical Trials Registry ensures transparency and adherence to international standards, which is crucial for regulatory approval and eventual widespread use. If successful, NV-387 could become a critical tool in combating Ebola and potentially other viral hemorrhagic fevers.
NanoViricides is a clinical-stage company that creates special purpose nanomaterials for antiviral therapy. The company's novel nanoviricide class of drug candidates and technology are based on intellectual property licensed from TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for developing drugs for all antiviral infections.
Beyond Ebola, NanoViricides is developing treatments for a range of viral diseases, including RSV, COVID-19, influenza, and herpes. The lead drug candidate NV-387 is also being studied for Mpox and other viral infections. The company's platform technology holds promise for broad-spectrum antiviral activity, which is particularly valuable in emerging viral outbreaks.
However, the path to drug approval is lengthy and requires substantial capital. NanoViricides notes that as with any drug development, there can be no assurance that its candidates will show sufficient effectiveness and safety for human clinical development. The company continues to advance its pipeline with a focus on addressing unmet medical needs in viral diseases.
The registration of this trial marks a step forward in the fight against Ebola, potentially offering a more accessible treatment option. The global health community will be watching the results closely, as an effective oral antiviral could transform outbreak response strategies.
